Iovance Biotherapeutics (IOVA) stock has been in focus after the company received U.S. Food and Drug Administration clearance to begin a Phase I/II basket trial for its next generation IL-12 tethered TIL therapy, IOV-5001.

The FDA clearance arrives after a strong run in Iovance Biotherapeutics stock, with the latest share price at $8.26 and a 30 day share price return of 75.74%. This has contributed to a year to date share price return of 227.78% and a 1 year total shareholder return of 270.40%. However, the 5 year total shareholder return is down 66.29%, which shows how recent momentum follows a much tougher longer term journey for holders.

Capitalize on the renewed interest in Iovance Biotherapeutics by scanning a hand picked set of solid balance sheet biotech and healthcare stocks in our list of solid balance sheet and fundamentals (50 results).

After such a sharp move in Iovance Biotherapeutics stock, some investors will see fresh upside potential while others worry the easy gains are already gone. The next step is to test that view against the current valuation.

Most Popular Narrative: 54.1% Undervalued

The most followed narrative on Iovance Biotherapeutics values the stock at $18.00 per share compared with the latest close at $8.26, which implies a large valuation gap according to that framework.

If the company successfully expands into:

• lung cancer,
• earlier lines of melanoma,
• combination therapies with checkpoint inhibitors,
• and eventually other solid tumors,

then the addressable market becomes several times larger than today.

Want to see what underpins that $18.00 fair value for Iovance Biotherapeutics? The narrative leans on aggressive revenue expansion, margin improvement and a richer future earnings multiple. Curious what specific product ramp and profitability path justify that gap to today’s share price? The full story lays out those assumptions in detail.

Result: Fair Value of $18.00 (UNDERVALUED)

However, investors still need to watch for clinical or regulatory setbacks in Iovance Biotherapeutics trials, and the company’s ongoing net losses could challenge long term valuation expectations.

Next Steps

After all this, do you feel the Iovance Biotherapeutics story leans more toward risk or reward? Take a closer look now and shape your own view with 2 key rewards and 2 important warning signs.

Looking for more Iovance Biotherapeutics investment ideas?

If the Iovance Biotherapeutics story has your attention, now is a good time to widen your watchlist so you are not relying on a single stock.

Use the Simply Wall Street Screener to quickly surface focused ideas that match different goals and risk levels.

• Target potential underpriced opportunities by scanning our 46 high quality undervalued stocks and compare how their fundamentals stack up against Iovance Biotherapeutics.
• Prioritise resilience and sleep better at night by filtering companies with lower risk profiles through the 76 resilient stocks with low risk scores before committing fresh capital.
• Get ahead of the crowd by reviewing a curated 20 high quality undiscovered gems that could complement or diversify your position alongside Iovance Biotherapeutics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.